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Abstract
Background: Genome wide association studies (GWAS) have revealed a large number of links between genome
variation and complex disease. Among other benefits, it is expected that these insights will lead to new
therapeutic strategies, particularly the identification of new drug targets. In this paper, we evaluate the power of
GWAS studies to find drug targets by examining how many existing drug targets have been directly ‘rediscovered’
by this technique, and the extent to which GWAS results may be leveraged by network information to discover
known and new drug targets.
Results: We find that only a very small fraction of drug targets are directly detected in the relevant GWAS studies.
We investigate two possible explanations for this observation. First, we find evidence of negative selection acting
on drug target genes as a consequence of strong coupling with the disease phenotype, so reducing the incidence
of SNPs linked to the disease. Second, we find that GWAS genes are substantially longer on average than drug
targets and than all genes, suggesting there is a length related bias in GWAS results. In spite of the low direct
relationship between drug targets and GWAS reported genes, we found these two sets of genes are closely
coupled in the human protein network. As a consequence, machine-learning methods are able to recover known
drug targets based on network context and the set of GWAS reported genes for the same disease. We show the
approach is potentially useful for identifying drug repurposing opportunities.
Conclusions: Although GWA studies do not directly identify most existing drug targets, there are several reasons
to expect that new targets will nevertheless be discovered using these data. Initial results on drug repurposing
studies using network analysis are encouraging and suggest directions for future development.
Introduction
Until recently, information on which variants within the
human genome contribute to increased risk of common
human disease was fragmentary and often statistically
weak. New chip-based technologies and large-scale
sequencing have now provided relatively unbiased and
reliable information on SNVs (single nucleotide variants)
and indels that are significantly associated with altered
risk for a number of common diseases. To date, most
information has been obtained through genome wide
association studies (GWAS) using microarray technol-
ogy, providing information only on common SNVs (the
single nucleotide polymorphisms, SNPs). The current
generation of GWA studies typically include several
thousand individuals with the disease of interest and a
similar number of control individuals without the dis-
ease. These studies and meta-analyses combining data
from multiple studies have now found more than 1600
loci where variants are associated with complex traits,
including many diseases (the GWAS catalog, http://
www.genome.gov/gwastudies).
There have been a number of discussions on the effi-
cacy of GWA studies [1]. In spite of the success in disco-
vering disease associations, it is becoming clear that
many disease mechanism genes with the highest effect on
disease phenotypes are not discovered by GWAS. Studies
of blood pressure provide a striking example. There is a
long history of identification of genes affecting blood
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pressure using non-genomic methods, and 30 genes dis-
covered in this way have provided successful targets for
treating hypertension [2]. But only a few of these candidate
genes and no drug targets are discovered in large scale
GWAS [3]. Further, mouse knockout data suggest that
some of the missing genes have very large effect sizes, with
blood pressure changes of 10s of mm of Hg [4], whereas
the largest changes associated with marker SNPs in
GWAS studies are between about 0.5 and 1 mm of Hg.
Known drug targets - genes that usually have a large
effect size on the corresponding disease phenotype, and
so should be found by GWAS - provide a means of
investigating whether non-discovery of mechanism
genes is a general phenomenon. Here, we compare a set
of reported mechanism genes in the GWAS catalog
(http://www.genome.gov/gwastudies [5], January 2012)
with a corresponding set of known drug target genes
(obtained from Drugbank [6], January 2012) for the
same diseases. We find that the overlap of these two
sets is very low. We also investigate two possible expla-
nations for low overlap. Finally, we consider the rela-
tionship between GWAS genes and drug targets in the
context of a protein functional interaction network, and
develop a machine learning method to predict new drug
targets using the relationship between GWAS genes and
known drug targets.
Results
Comparison of the GWAS catalog and Drugbank shows
GWAS only detects a very small fraction of existing drug
targets
We examined the relationship between genes in the
GWAS catalog [5] and drug target genes in Drugbank [6].
The GWAS catalog (http://www.genome.gov/gwastudies/)
is a comprehensive collection of results from published
GWAS studies on a wide variety of disease and other traits
such as height. Drugbank [6] is a database that combines
detailed drug (i.e. chemical, pharmacological and pharma-
ceutical) data with comprehensive drug target information
(sequence, structure, and pathway). We compiled a list of
disease related traits in the GWAS catalog and extracted
the reported genes for each of them. The disease list
includes a number of cancers, a variety of complex trait
diseases, and disease predisposition traits such as obesity
and hypertension. We then found the drugs used in treat-
ment of each of these traits in Drugbank, and extracted
the drug target genes for each drug. Thus, for each trait,
we have a list of GWAS reported genes and a list of drug
targets. For the 88 GWAS diseases that have drugs in
Drugbank, there are on average 29.2 GWAS reported
genes and 24.0 drug targets for 19.9 drugs (Table 1).
There are a total 23 instances of GWAS genes that are
also drug targets for the same disease. Three of these
genes are each drug targets for two different diseases, so
that only 20 of the 856 drug target genes have been dis-
covered in GWA studies of the corresponding traits. This
is slightly larger than the overlap of approximately 5 from
a completely random model, but is a very low number
considering that altered activity of most drug target genes
will influence the disease phenotype.
Possible data related reasons for low overlap
One possible cause of lower overlap is that in Drugbank,
some drug targets do not have a known mechanism and
are probably ‘predicted’ targets based on sequence simi-
larity to other verified drug targets [7,8], and thus may
be incorrect. We therefore compiled a list of verified
drug targets, all of which have known drug action
mechanisms documented in Drugbank. We find similar
results with this set to those for the complete list of
drug targets. For those 353 drug targets for 81 diseases
with known mechanisms and with corresponding
GWAS studies, only 12 are discovered by GWAS (Addi-
tional file 1). On average, in this set there are 30 GWAS
reported genes and 11.2 verified drug targets for each of
these 81 diseases. A second possible cause of low over-
lap is mis-assignment of mechanism genes in the
GWAS catalog. Marker SNPs (those associated with a
trait) found in a GWAS locus are usually in linkage dis-
equilibrium with many other SNPs covering a number
of genes, any of which in principle might be in disease
mechanism. In some cases, the catalog assignments may
be incorrect, and the true mechanism gene in a locus
may in fact be a drug target. We investigated the effect
of this factor by comparing drug target/GWAS overlap
described above with that obtained including all genes
in each locus as candidates, rather than just those
reported as candidates in the GWAS catalog. For the 58
diseases with sufficient information in the catalog, link-
age disequilibrium expansion from marker SNPs
increased the set of candidate genes from the 1997
reported to 4035, about a factor of two. The number of
GWAS genes that are also drug targets increased from
18 to 24. This small increase is comparable with the
increase of 3 that is expected from the random model.
Thus, the number of GWAS/drug target matches missed
as a consequence of misidentification of candidate genes
appears very small. A third data related factor is cover-
age by the tag SNPs on the microarrays used in GWAS
studies. If there is no tag SNP in linkage disequilibrium
with the underlying variant involved in a disease
mechanism, that contribution to the trait will not be
detected. A study of 160 non-GWAS derived candidate
genes for blood pressure concluded that only half were
adequately covered with tag SNPs on a 500K array [3],
suggesting this is a significant factor. But overall, data
considerations do not qualitatively change the picture of
very low GWAS gene/drug target overlap.
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Acute lymphoblastic leukemia 6 19 10 0 3
Age-related macular degeneration 9 23 2 1 2
Allergic rhinitis 69 11 20 0 5
Alzheimer’s disease 5 54 179 0 40
Amyotrophic lateral sclerosis 3 26 2 0 1
Ankylosing spondylitis 39 17 29 0 9
Arthritis 168 7 112 0 35
Asthma 102 43 52 1 19
Atopic dermatitis 12 8 3 0 1
Atrial fibrillation 45 7 25 0 14
Attention deficit hyperactivity disorder 3 81 1 0 1
Autism 3 6 10 0 5
Basal cell carcinoma 6 8 9 0 2
Bipolar disorder/Schizophrenia 93 215 110 1 32
Blood pressure/Hypertension 351 100 114 3 35
Breast cancer 84 42 43 1 13
Celiac disease 3 74 1 0 0
Chronic kidney disease 8 69 6 0 2
Chronic lymphocytic leukemia 14 17 29 0 5
Chronic myeloid leukemia 6 9 15 0 6
Chronic obstructive pulmonary disease 14 18 7 0 2
Colorectal cancer 8 14 16 0 6
Coronary heart disease 6 84 5 0 3
Crohn’s disease 7 136 23 0 9
Cystic fibrosis 8 7 11 0 5
Depression/Depressive disorder 45 68 73 0 17
Diabetes 46 205 59 4 21
Duodenal ulcer 8 2 18 0 5
Emphysema 10 5 17 0 5
Endometrial cancer 1 2 2 0 0
Endometriosis 5 4 7 0 3
End-stage renal disease 2 2 8 0 3
Epilepsy 18 1 53 0 10
Esophageal cancer 1 18 2 0 1
Gallstones 1 1 1 0 0
Gastric cancer 2 3 1 0 0
Glaucoma 24 13 31 0 6
Glioblastoma 2 1 1 0 0
Heart failure 51 16 65 0 27
HIV/AIDS 54 62 53 1 9
Hodgkin’s lymphoma 8 7 31 0 7
Hypertriglyceridemia 2 5 4 0 3
Hypothyroidism 5 43 8 1 5
Inflammatory bowel disease 2 18 8 0 4
Kawasaki disease 1 20 11 1 5
Malaria 17 3 17 0 4
Male infertility 6 5 3 0 3
Melanoma 9 20 6 0 0
Menopause age 9 23 15 0 4
Migraine 20 7 46 0 10
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Analysis using 1000 genomes data shows Drug Target
genes have fewer high frequency non-synonymous SNPs
than GWAS reported genes
We next consider two possible reasons why GWAS
identifies so few known drug targets. A study of all the
SNPs in the GWAS catalog [5] has shown that reported
SNPs are common (median risk allele frequency 36%,
interquantile range (IQR) 21%-53%), and are associated
with modest effect size (median odds ratio 1.33, IQR
1.20-1.61). We speculated that drug target genes may
escape GWAS studies because these contain few com-
mon SNPs that affect function. To test this hypothesis,
we examined the distribution of SNP frequencies and
SNP effect size in GWAS identified genes and drug tar-
gets, using SNP frequencies calculated from 1000 gen-
omes data [9].
A SNP may affect in vivo function of a gene product
through a number of different mechanisms, including
modified protein function or protein stability, altered
regulation of gene expression, modified splicing, and
changed stability of messenger RNA. We focus on non-
synonymous SNPs, which have been shown to be signifi-
cantly overrepresented at amongst GWAS marker SNPs
[5]. We found that drug targets genes do have fewer
non-synonymous SNPs (0.0155/residue vs. 0.0171/resi-
due) and the tendency is more significant for common
Table 1 Overlap between GWAS reported genes and drug targets (Continued)
Multiple myeloma 7 3 10 0 3
Multiple sclerosis 10 123 30 1 12
Myocardial infarction 29 14 44 0 17
Narcolepsy 2 4 6 0 1
Nephropathy/Nephrotic syndrome 20 26 38 0 9
Neuroblastoma 2 2 6 0 2
Non-small cell lung cancer 5 7 10 0 1
Obesity 4 40 11 0 4
Osteoarthritis 26 3 46 0 10
Osteoporosis 13 10 10 0 2
Ovarian cancer 5 10 4 0 1
Paget’s disease 4 9 6 0 1
Pancreatic cancer 2 29 11 0 4
Panic disorder 6 10 18 0 4
Parkinson’s disease 20 62 184 1 34
Polycystic ovary syndrome 2 7 2 0 1
Prostate cancer 14 94 21 0 8
Psoriasis/Psoriatic arthritis 19 30 39 0 13
Refractive error 1 4 4 0 1
Restless legs syndrome 2 6 18 0 6
Rheumatoid arthritis 46 67 80 2 29
Sleepiness 1 2 2 0 0
Stevens-Johnson syndrome/toxic
epidermal necrolysis
1 12 1 0 0
Stroke 8 4 7 0 6
Tardive dyskinesia 3 1 22 0 7
Testicular cancer 4 7 6 0 2
Thyroid cancer 2 5 3 0 2
Tuberculosis 12 5 18 0 4
Type 1 diabetes 8 74 18 0 8
Type 2 diabetes 28 91 34 3 13
Ulcerative colitis 5 95 9 1 6
Uterine fibroids 1 7 1 0 0
Venous thromboembolism 1 7 3 0 2
Vitiligo 4 25 8 1 2
Mean 19.90 29.18 24.00 0.26 7.09
*For each disease, the number of GWAS reported genes that are also drug targets for the disease.
**For each disease, the number of GWAS reported genes that are drug targets for any disease.
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(Allele frequency > 5%) non-synonymous SNPs
(0.00169/residue vs. 0.00221/residue, Mann-Whitney
test P = 0.0017) (Table 2). We also included a set of
predominantly monogenic disease genes from the
Human Gene Mutation Database (HGMD) [10], expect-
ing these to also be under negative selection pressure.
SNP density is also lower in this class of genes. A possi-
ble explanation for the low occurrence of common
SNPs is that the activity level of drug targets genes is
strongly coupled to the disease phenotype. As a result
they are under relatively high selection pressure, and
SNPs with a substantial impact on function will be
eliminated or tend to be at a low frequency.
Evolutionary analysis shows drug target genes are under
slightly stronger negative selection than GWAS reported
genes
If the drug targets genes are under stronger selection as
we propose on the basis of SNP density, that effect
should also be observable in the rate of sequence change
during the evolutionary history of the gene family. The
ratio of the rate of non-synonymous to synonymous
change, dN/dS, [11] for a gene provides one measure to
detect such selection pressure. We compared the dN/dS
for GWAS and drug target genes using human-mouse
and human-chimp data from H-invDB [12] and found
both are under stronger selection (Table 3) than all
genes. We found HGMD genes [10] also exhibit nega-
tive selection in recent history (dN/dS calculated using
human-chimp orthologs). The selection against variants
in drug target genes is slightly stronger than that against
variants in GWAS reported genes (Table 3) for dN/dS
calculated using human-chimp orthologs, suggesting the
selection is stronger for drug targets in recent history.
The influence of transcript length
For some mechanisms, for example those arising from
missense SNPs, the probability of contributing to a com-
plex trait is dependent on the length of the gene
affected: Under similar selection pressures, the longer
the gene, the more likely variants affecting gene function
will be present. Other mechanisms, such as those
directly affecting transcription rate, are not length
dependent. To test for a length effect, we examined the
length distribution for GWAS reported genes, for drug
targets, and for all genes (Figure 1). GWAS reported
genes are significantly longer than the drug target genes
(paired Mann-Whitney test, P = 1.89e-6) and GWAS
reported genes tend to be longer than all other genes.
The mean longest transcript length for GWAS reported
genes is about 110K while the mean longest transcript
length for drug targets is about 60K, almost a factor two
different. The outlier here is the GWAS gene set - drug
targets have a similar distribution to that of all genes.





P Value for Mann-Whitney test
against all genes




All genes 13691 0.22
GWAS reported genes 2932 0.19 2.44e-09*
Drug targets 1035 0.18 1.21e-04* 0.43
Drug targets with
known mechanism
432 0.17 6.04e-06* 0.038*




All genes 14173 0.44
GWAS reported genes 2911 0.36 1.26e-13*
Drug targets 1020 0.33 2.78e-13* 0.0098*
Drug targets with
known mechanism
423 0.32 4.20e-08* 0.013*
HGMD genes 699 0.36 0.002*
“*” denotes significant, i.e, P < 0.05
Table 2 Comparison of common non-synonymous SNP densities between GWAS reported genes and drug targets
Drug Targets GWAS reported genes HGMD genes All genes
Density of all non-synonymous SNPs 0.0155 0.0171 0.0166 0.0171




1P-value for Mann-Whitney test against the density of common non-synonymous SNPs for GWAS reported genes.2P-value for Mann-Whitney test against the
density of common non-synonymous SNPs for all genes.
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Thus there is a strong length factor influencing whether
or not variants in a gene contribute to a complex trait.
This result is consistent with a role for length depen-
dent mechanisms, although there could be other
explanations.
Network analysis shows GWAS reported genes are close to
drug target genes in a biological network
Although most drug targets are not identified through
GWAS studies, they are obviously as much involved in
the disease mechanism as GWAS genes, and so may be
expected to have similar properties, particularly in terms
of pathway and network relationships. A number of stu-
dies have incorporated network information to aid in
identifying various classes of genes, for example using a
network module formalism to combine signals from
multiple GWAS studies [13,14] and using network flow
models to predict drug targets from expression and
other data in prostate cancer [15]. Network models have
also been used to identify pathways implicated in cancer
[16]. It has already been observed that GWAS genes are
substantially more closely connected in a functional net-
work [17] than random genes, and we expect that to be
the case for other large effect genes, such as known
drug targets.
There are many resources available for different types
of human biological networks. Protein-Protein interac-
tion data [18,19] have a wide coverage but usually have
a high false positive rate. Curated pathways such as
Figure 1 Distribution of the log longest transcript length for different types of genes. GWAS genes are on average substantially longer
than drug target genes, and longer than the set of all genes.
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KEGG [20] and BioCarta (http://www.biocarta.com/
genes/index.asp) are considered to be more accurate but
the coverage is sparse [21]. For our purposes, networks
built from other kinds of relationship, such as regulatory
networks deduced from micro-array data [22,23] or net-
works based on biochemical reactions [24] are too nar-
row in terms of the interactions they capture.
In this study, we use the Functional Interaction (FI)
network from [21], a protein functional interaction net-
work generated by extending curated biological path-
ways with non-curated sources of information, including
protein-protein interactions, gene co-expression, protein
domain interaction, Gene Ontology (GO) annotations
and text-mined protein interactions, and covering about
50% of human genes. The network strikes a balance
between experimentally validated results and prediction,
with the prediction portion benchmarked by a reason-
ably rigorous process. We were able to map 611 out of
821 drug targets genes and 1125 out of 1914 GWAS
reported genes for the 88 diseases to the network.
Examination of the network proximity of GWAS genes
to each other and to drug targets for the same disease
indeed shows a close-nit matrix of relationships. Figure 2
shows the network formed for the 43 GWAS and 16 drug
target genes [6] for Type I Diabetes that project onto the
FI network, and only including genes from these two sets
which are linked by not more than one other intermediate
gene. All drug targets and all but five of the GWAS genes
form part of a single continuous sub-network. This sug-
gests that the two sets of genes are indeed relatively close
Figure 2 Continuous network substructure formed by 43 of the 74 GWAS (green) and 16 of the 18 drug targets (red) for Type 1
Diabetes, allowing not more than one intermediate gene (grey). GWAS and drug target genes are intermingled in the network, and short
paths are sufficient to form a connected network for almost all genes. FI network, figure from Cytoscape.
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in their biological function. One measure of the relation-
ship between GWAS reported genes and drug target genes
is the closeness of each GWAS gene to its nearest drug
target (Figure 3). The distributions show that distances
from a GWAS reported gene to the closest drug target are
on average much shorter than those of a random gene to
a closest drug target, and the shortest distance from a
drug target gene to the closest GWAS reported gene is
also shorter than that of a random gene to the closest
GWAS reported gene. Notably, drug targets are about
Figure 3 A. Distribution of shortest distances to the nearest drug target for GWAS reported genes and all genes. B. Distribution of
the shortest distance to the nearest GWAS genes for drug targets and all genes. C. Distribution of degree for drug targets and all
genes in the FI network. Drug targets have a slightly higher degree (Mann-Whitley test P = 0.014).
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three fold enriched in the first neighbors of GWAS genes
and are also enriched in GWAS second neighbors (genes
two steps away in the gene network) (Figure 3).
Highly connected genes have more neighbors, and
thus are more likely to include GWAS genes as neigh-
bors. Thus, the observed enrichment of short paths
between drug targets and GWAS genes could partially
be a consequence of higher connectivity for drug targets.
To control for this effect, we compared the degrees of
drug targets with all genes (Figure 3) and found drug
targets have a slightly higher degree (Mann-Whitney
test, P = 0.014) on average. However the difference is
marginal, and is unlikely to significantly contribute to
the substantial difference between the short path distri-
bution for drug targets and all genes.
A machine learning method for drug target discovery
The relationship between drug targets and GWAS genes
revealed in the network analysis suggests that it should
be possible to identify potential new drug targets from
GWAS genes using machine learning methods trained
on network features. The idea is to evaluate the prob-
ability that any gene is a potential drug target, given its
network environment. The environment of each gene is
represented by a set of features. Since we observed a
threefold enrichment of drug targets in the first neigh-
bors of the GWAS genes, we use the number of GWAS
neighbors for a gene as a feature. This quantity is highly
dependent on the total number of neighbors a gene has,
so we also use the degree of the gene as a control. As
the previous analysis shows, second neighbors of drug
targets genes (genes that are two steps away in the pro-
tein interaction network) are also enriched for GWAS
genes, thus we also use the number of second neighbor
GWAS genes of a gene as a feature. These three fea-
tures capture the enrichment information from the ana-
lysis above, but there are some subtle relationships not
included. The problem of identifying drug targets based
on their relationship to GWAS genes is similar to the
problem of finding missing relationships in social net-
work analysis. We therefore also use common friends
with GWAS genes, a widely used feature in the social
network machine learning field [25]. The common
neighbor feature is defined as the proportion of neigh-




In which NA is the set of Neighbors for gene A, NB is
the set of Neighbors for gene B.
The total number of features for each gene is 3+N,
where N is the number of GWAS genes for that disease
that are mapped to the protein network. Since the num-
ber of drug targets (average 30) for a disease is very
small compared to the total number of genes in the FI
network (10956), the training set is highly unbalanced if
we use the latter as the true negative set. To address this
issue, we focus on the 932 existing drug targets in Drug-
bank that are also in the FI network, and thus restrict the
task to identifying targets for existing drugs that can
potentially be repurposed to treat other diseases. Repur-
posing is an attractive goal, since such use is much easier
than developing a new drug from scratch [26].
We include the 30 diseases with at least 10 approved
drug targets and 10 GWAS genes in the FI network. We
tested four machine learning methods using the WEKA
software package [27]: a SVM with a polynomial kernel, a
SVM with a RBF kernel, a Naïve Bayes Network, and
Random Forests. Among these the best result is achieved
by a Random forest (Table 4). The best case is Kawasaki
disease, with a true positive rate of 70% (recovering seven
out of the 10 known drug targets) and a false positive
rate of 2.7%.
Potential new drug targets for drug repurposing
The ‘false positive’ drug targets are drug targets for
other diseases which have very similar network proper-
ties to those of the disease under study. These may
indeed be mistakes made by the classifier. However,
some of these ‘false positive’ drug targets may be good
candidates for repurposing, not previously identified.
For example, C1QB and C1QC are the highest scoring
proteins in the false positive list for the best case, Kawa-
saki disease, These are subcomponents of complement
C1Q. C1Q has been shown to be associated with lupus
erythematous [28-30], another autoimmune disease
related to Kawasaki disease [31,32], consistent with rele-
vance to Kawasaki. C1Q is the target of several FDA
approved drugs, for example, Etanercept, a drug treating
rheumatoid arthritis and Adalimumab, a drug treating
rheumatoid arthritis, psoriatic arthritis, ankylosing spon-
dylitis, and other immune system mediated diseases.
Thus these drugs may be potential candidates for use
against Kawasaki disease.
Another disease where the method performs well is
acute lymphoblastic leukemia (ALL), with a false posi-
tive rate of 7% and a true positive rate of 70%. There is
a relatively long list of ‘false positive’ targets (Table 5).
Careful inspection of these genes reveals some that may
have relevance to acute lymphoblastic leukemia, and so
drugs for which these are targets provide potential can-
didates for repurposing. For example, chromosomal
aberrations (i.e. chromosome translocation) in FGFR1
are associated with stem cell myeloproliferative disorder
and stem cell leukemia lymphoma syndrome (provided
by RefSeq, Jul 2008). FGFR1 is the drug target of Palifer-
min, a recombinant human keratinocyte growth factor
(KGF) for the treatment of oral mucositis associated
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with chemotherapy and radiation therapy. It’s also the
target for several experimental drugs.
A second potential repurposing target for acute lym-
phoblastic leukemia is the oncogene RET. Previous stu-
dies found differential expression of RET in acute
myeloid leukemia [33], a distinct but related leukemia. In
the version of Drugbank used in this analysis, there is no
drug targeting RET for the treatment of ALL. Recently,
however, the drug Ponatinib has been approved by the
FDA for treatment of Philadelphia chromosome positive
acute lymphoblastic leukemia (Ph+ALL) resistant or
intolerant to prior tyrosine kinase inhibitor therapy.
Thus, one of the high scoring ALL potential drug
targets has now been approved for use for use with a new
drug.
Methods
Connecting GWAS reported genes with drug targets
using drug indication information from Drugbank
GWAS reported genes: The GWAS catalog was down-
loaded from http://www.genome.gov/admin/gwascatalog.
txt in January 2012. Non-disease traits were removed by
hand and multiple studies for each disease were com-
bined into unique sets. ‘Reported genes’ were extracted
to provide the list of GWAS genes for each disease.
Drug targets: Drugbank data were downloaded from
http://www.drugbank.ca/downloads in January 2012.
Drugs for each disease in the GWAS list were identified
by searching the ‘indication’ information for all drugs in
Drugbank. Then for each of these drugs, we extract all
of the corresponding target genes.














Ankylosing spondylitis 17 29(24) 0.36 0.123 0.074 0.36 0.73 0.123
Menopause 24 15(14) 0.571 0.098 0.082 0.571 0.819 0.143
Multiple sclerosis 126 30(28) 0.393 0.052 0.19 0.393 0.75 0.256
Myocardial infarction 14 44(40) 0.175 0.135 0.055 0.175 0.571 0.084
Nephropathy/Nephrotic
syndrome
26 38(35) 0.371 0.245 0.056 0.371 0.576 0.097
Obesity 40 11(11) 0.273 0.098 0.032 0.273 0.724 0.058
Osteoporosis 10 10(10) 0.2 0.189 0.011 0.2 0.546 0.022
Pancreatic cancer 29 11(6) 0.167 0.1 0.011 0.167 0.611 0.02
Panic disorder 10 18(16) 0.438 0.118 0.061 0.438 0.754 0.107
Parkinson’s disease 62 184(132) 0.606 0.226 0.307 0.606 0.712 0.407
Asthma 43 52(47) 0.213 0.102 0.1 0.213 0.713 0.136
Prostate cancer 95 21(18) 0.5 0.073 0.118 0.5 0.686 0.191
Psoriasis/Psoriatic arthritis 31 39(36) 0.5 0.076 0.209 0.5 0.852 0.295
Rheumatoid arthritis 67 80(68) 0.324 0.131 0.163 0.324 0.677 0.217
Type 1 diabetes 76 18(16) 0.25 0.104 0.04 0.25 0.631 0.07
Type 2 diabetes 92 34(28) 0.214 0.116 0.054 0.214 0.595 0.086
Bipolar disorder/Schizophrenia 217 110(81) 0.593 0.15 0.273 0.593 0.744 0.374
Blood pressure/Hypertension 101 114(102) 0.412 0.143 0.261 0.412 0.717 0.319
Breast cancer 43 43(38) 0.289 0.072 0.147 0.289 0.745 0.195
Chronic lymphocytic leukemia 17 29(26) 0.423 0.098 0.11 0.423 0.653 0.175
Colorectal cancer 14 16(16) 0.25 0.154 0.028 0.25 0.53 0.05
Acute lymphoblastic leukemia 19 10(10) 0.7 0.07 0.097 0.7 0.889 0.171
Crohn’s disease 139 23(22) 0.455 0.093 0.105 0.455 0.764 0.171
Depression/Depressive disorder 68 73(62) 0.597 0.172 0.198 0.597 0.722 0.297
Diabetes 209 59(51) 0.216 0.081 0.134 0.216 0.712 0.165
Allergic rhinitis 11 20(19) 0.263 0.128 0.041 0.263 0.589 0.071
Glaucoma 14 31(25) 0.16 0.189 0.023 0.16 0.443 0.04
Alzheimer’s disease 54 179(125) 0.544 0.178 0.321 0.544 0.69 0.404
Heart failure 16 65(54) 0.481 0.222 0.118 0.481 0.655 0.189
HIV/AIDS 63 53(34) 0.353 0.121 0.099 0.353 0.715 0.155
Kawasaki disease 20 11(10) 0.7 0.027 0.219 0.7 0.919 0.333
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Verified drug targets: Drug targets with the entry
“Pharmacological action” labeled as ‘Yes’ in the Drugbank.
All 4013 GWAS reported genes and 1463 drug targets
were mapped to NCBI gene IDs to provide unique identi-
fiers for comparison. For the 88 GWAS diseases with
drugs in Drugbank, there are 1914 GWAS reported genes
and 821 drug targets. The verified drug target set has 353
genes for 81 diseases. For each disease, we compare the
list of GWAS reported genes and drug targets and find the
overlap between these two lists.
Calculating expected overlap between GWAS reported
genes and drug targets using a random model
We assume there are 20,000 human genes. For a specific
disease, if there are ‘m’ GWAS reported genes, and there
are ‘n’ drug targets for this disease the expected random
Table 5 Top ‘false positive’ drug targets for acute lymphoblastic leukemia.
Target Description from Refseq Random Forest
Probability
MAPK3 The protein encoded by this gene is a member of the MAP kinase family. MAP kinases, also known as extracellular
signal-regulated kinases (ERKs), act in a signaling cascade that regulates various cellular processes such as
proliferation, differentiation, and cell cycle progression in response to a variety of extracellular signals.
1
PIK3R1 Phosphatidylinositol 3-kinase plays an important role in the metabolic actions of insulin, and a mutation in this
gene has been associated with insulin resistance.
0.96
RAF1 v-raf-1 murine leukemia viral oncogene homolog 1 0.96
EGFR Mutations in this gene are associated with lung cancer. Multiple alternatively spliced transcript variants that encode
different protein isoforms have been found for this gene
0.96
FGFR2 Mutations in this gene are associated with Crouzon syndrome, Pfeiffer syndrome, Craniosynostosis, Apert syndrome,
Jackson-Weiss syndrome, Beare-Stevenson cutis gyrata syndrome, Saethre-Chotzen syndrome, and syndromic
craniosynostosis.
0.96
KDR This receptor, known as kinase insert domain receptor, is a type III receptor tyrosine kinase. Mutations of this gene
are implicated in infantile capillary hemangiomas.
0.94
FLT1 This protein binds to VEGFR-A, VEGFR-B and placental growth factor and plays an important role in angiogenesis
and vasculogenesis.
0.94
FGFR1 Chromosomal aberrations involving this gene are associated with stem cell myeloproliferative disorder and stem
cell leukemia lymphoma syndrome.
0.94
IL2RG The protein encoded by this gene is an important signaling component of many interleukin receptors 0.92
ERBB2 v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog 0.92
FGFR3 This particular family member binds acidic and basic fibroblast growth hormone and plays a role in bone
development and maintenance. Mutations in this gene lead to craniosynostosis and multiple types of skeletal
dysplasia.
0.9
AKT1 v-akt murine thymoma viral oncogene homolog 1 0.9
INSR insulin receptor 0.9
IL2RA Mutations in this gene are associated with interleukin 2 receptor alpha deficiency. 0.9
SDC2 The syndecan-2 protein functions as an integral membrane protein and participates in cell proliferation, cell
migration and cell-matrix interactions via its receptor for extracellular matrix proteins. Altered syndecan-2 expression
has been detected in several different tumor types.
0.88
MAPK1 The protein encoded by this gene is a member of the MAP kinase family. MAP kinases, also known as extracellular
signal-regulated kinases (ERKs), act as an integration point for multiple biochemical signals, and are involved in a
wide variety of cellular processes such as proliferation, differentiation, transcription regulation and development.
0.86
CD247 The protein encoded by this gene is T-cell receptor zeta, which together with T-cell receptor alpha/beta and
gamma/delta heterodimers, and with CD3-gamma, -delta and -epsilon, forms the T-cell receptor-CD3 complex.
0.86
RET ret proto-oncogene 0.86
VEGFA vascular endothelial growth factor A 0.86
PTPN1 protein tyrosine phosphatase, non-receptor type 1 0.86
IL3RA The protein encoded by this gene is an interleukin 3 specific subunit of a heterodimeric cytokine receptor. 0.84
HDAC1 histone deacetylase 1, Together with metastasis-associated protein-2, it deacetylates p53 and modulates its effect
on cell growth and apoptosis.
0.82
CCND1 The protein encoded by this gene belongs to the highly conserved cyclin family, whose members are characterized
by a dramatic periodicity in protein abundance throughout the cell cycle. This protein has been shown to interact
with tumor suppressor protein Rb and the expression of this gene is regulated positively by Rb. Mutations,
amplification and overexpression of this gene, which alters cell cycle progression, are observed frequently in a
variety of tumors and may contribute to tumorigenesis
0.82
FASN fatty acid synthase 0.82
CD4 The protein functions to initiate or augment the early phase of T-cell activation, and may function as an important
mediator of indirect neuronal damage in infectious and immune-mediated diseases of the central nervous system.
0.8
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overlap between the two gene lists for that disease is
n*m/20000. We calculated the expected overlap for each
disease and summed these to get the expected total
number of overlaps between drug targets and GWAS
reported genes for the same disease.
SNP impact analysis for GWAS genes and drug target genes
1000 genomes VCF data were downloaded from http://
www.1000genomes.org/data. The 2010 November data
set is used. We extracted all non-synonymous variants
from 1000 genomes data based on Refseq annotation
downloaded from the UCSC genome browser in Jan
2012, and calculated the allele frequency for each of the
non-reference variants by dividing the number of alleles
(count 1 for heterozygous and 2 for homozygous) by the
number of total possible (2 times the number of people).
We found non-synonymous SNPs in the coding regions
of 3550 out of the 4013 GWAS reported genes and 1249
out of the 1463 drug targets.
The density of common non-synonymous SNPs in each
gene is calculated by dividing the number of non-synon-
ymous SNPs with frequencies > 5% for that gene by the
length of that gene’s protein sequence provided by the
UCSC genome browser http://genome.ucsc.edu/. One
splicing form is randomly chosen for each NCBI gene ID.
Transcript length analysis
The longest transcript for each drug target and GWAS
reported gene was picked based on the Refseq annotation
downloaded from the UCSC genome browser in Jan 2012.
Evolutionary analysis for GWAS reported genes and Drug
target genes
Ratios of non-synonymous to synonymous substitution
rates, dN/dS, for human proteins were downloaded from
http://www.h-invitational.jp/evola/download.html in
March 2012. The h-inv [34] IDs were converted to NCBI
Gene IDs using a conversion map downloaded from
http://biodb.jp/download.cgi. dN/dS from Human-Mouse
orthologs and Human-Chimpanzee orthologs were
selected. Human-Mouse dN/dS are considered to reflect
selection over a relatively long time period, and Human-
Chimpanzee dN/dS to reflect more recent history.
Human gene network analysis for GWAS reported genes
and drug target genes
The Functional Interaction protein network [21] was
downloaded from http://genomebiology.com/content/sup-
plementary/gb-2010-11-5-r53-s3.zip. This un-weighted
map consists of 209,988 functional interactions involving
10956 proteins, and covers roughly half of the human cod-
ing genome. Gene symbols in this data set were converted
to NCBI gene IDs. 1125 out of 1914 GWAS reported genes
and 611 out of 821 drug target genes for the 88 diseases
and 932 drug targets of all 1463 drug targets were mapped
into the network.
The Floyd-Warshall algorithm [35] was used to calcu-
late the shortest path between all gene pairs in the net-
work. The resulting set of inter-node distances serves as
a background distribution. For each disease, we extracted
the set of all pairwise distances between GWAS genes for
that disease, between drug targets genes, and between
GWAS genes and drug target genes. For each disease, we
also calculated the shortest path from every gene in the
network to the nearest GWAS gene for that disease and
to the nearest drug target for the disease.
Machine learning for drug targets
We used a random forest implemented in WEKA [27]
to train on the N+3 features to predict known drug tar-
gets for a disease from the set of all drug targets. The
training sets are unbalanced since the number of drug
targets for each disease is very small (median 28) com-
pared to all possible drug targets, 932. We use the
MetaCost procedure [36] to deal with the unbalanced
training set, which gives more penalty to false negative
errors than to false positive errors. We set the cost fac-
tor to be the ratio between the number of ‘correct’ and
‘incorrect’ drug targets. We set the parameter K, the
number of separating features, as the square root of the
number of all features and set the parameter I, the num-
ber of decision trees in the random forest, as 50. 10 fold
cross validation was used to measure the performance
for the random forest method for each disease.
Discussion
This work began with an evaluation of the capability of
GWA studies to identify existing drug targets for com-
plex trait disease, based on a comparison of proposed
disease mechanism genes in the GWAS catalog and
drug targets in Drugbank. To our surprise, only 20 of
these 856 drug targets correspond to GWAS identified
mechanism genes. Although the point is not emphasized
there, a recent study also found a small level of overlap
between GWAS disease genes and corresponding drug
targets for approved drugs [37] (16 compared with our
20, based on fewer GWAS genes, Table S3 in [37]).
Interestingly, that study found that inclusion of targets
for drugs at all stages of development boosts the overlap
considerably, to 63. Thus it appears that drugs currently
being developed are more commonly GWAS genes than
those already approved, perhaps because new studies are
now selecting targets from GWAS results. Another
study has examined the possibility of repurposing based
on overlap between OMIM disease genes and drug tar-
gets [38], and reports a higher level of overlap.
We investigated two possible reasons why the overlap
of GWAS results and drug targets is so low. First, there
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may be more selection against SNPs with significant
impact in drug targets. Studies [5] have shown that
GWAS methods typically find high frequency SNPs with
modest phenotype effects. On the other hand drug targets
have big effect sizes with respect to disease phenotypes.
Thus there may be fewer high frequency deleterious SNPs
in these genes. Indeed, we do observe this trend for non-
synonymous SNPs through analysis of population geno-
mics data from the 1000 genomes project. It is likely that
SNPs exerting their influence through other mechanisms
(for example, altering the regulation of the expression of
genes, changing the splicing pattern, or changing the stabi-
lity of messenger RNA) also follow the same pattern since
selection pressure is independent of impact mechanism.
This finding of apparent selection pressure against variants
with impact on drug target activity is supported by the
observation of similar trends in acceptance of species-spe-
cific changes, as measured through dN/dS.
The second possible reason why GWAS genes and
drug target overlap is small that we investigated con-
cerns the relative length of GWAS genes versus drug
targets. We find that on average GWAS genes are very
significantly longer than drug targets, by about a factor
of two, and also longer than the set of all genes. These
data suggest that mechanisms that are more likely to
occur in longer transcripts, such as those involving mis-
sense SNPs, play a significant role in complex traits.
The data do not rule out other explanations for the
length differences, but in any case there is a strong
length bias in GWAS genes.
These two factors - selection against common SNPs in
drug targets and longer length of GWAS genes - are sig-
nificant but may not be the only factors contributing to
very low drug target/GWAS gene overlap. As discussed
earlier, loss of overlap from data errors does not appear
large, but incomplete coverage by typical microarrays is
a contributing factor [3]. There are some other factors
that will contribute. Drugs may act to alleviate symp-
toms rather than affect the disease itself or they may act
in a more global non-specific manner, for example gen-
erally suppressing inflammation rather than influencing
a specific disease. Also, drugs typically decrease the in
vivo activity of the protein concerned, whereas altered
activity of mechanism genes may affect disease traits
through either a decrease or an increase of in vivo activ-
ity (for example, a SNP may result in up-regulation of
expression, contributing to disease risk).
The fact that most existing drug targets are not redis-
covered by GWAS does not necessarily imply that few
new drug targets will be directly discovered through this
technology. For example, many drug targets for inflam-
matory diseases provide general reduction of inflamma-
tion, while its possible that GWAS may lead to much
more disease specific targets. What is clear is that the
close relationship between drug targets and GWAS
reported genes makes the GWAS genes valuable net-
work reference points for finding new drug targets. We
have shown that relatively simple machine learning
methods are effective at identifying potential drug repur-
posing opportunities, and one of our initial short-listed
repurposing candidates has now been approved for use
by the FDA. There is clearly considerable scope for
more sophisticated methods, employing a combination
of network and pathway information.
The present GWAS technology is only able to detect
disease associations involving common SNPs. There are a
large number of rare variants in the human exome [39]
and as exome sequence and full genome sequence replace
DNA microarrays in GWAS studies [40], the role of these
is becoming better defined. A deep re-sequencing project
for drug target genes has found an abundance of rare
functional variants [41] and these are likely to play a role
in complex disease. For some diseases, such as hyperten-
sion, many candidate genes have been proposed using
non-genomic methods [2]. Rare variants in these candidate
genes in patients will also be of great interest.
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